Introduction. Psoriatic arthritis (PsA) is an inflammatory joint disease associated in up to one-third of patients with psoriasis. Studies performed on PsA showed the high burden of the disease, but it still has not been totally quantified due to variable course of the disease. The applicability of the existing clinical tools in the disease activity appreciation still needs to be approved.

The objective of the study was the assessment of the disease activity level and the evaluation of reliability and applicability of disease activity measures in PsA.

Materials and methods. A descriptive study of 46 PsA patients was performed. The disease activity indices for PsA were evaluated and compared. The level of the disease activity according to each index was assessed and applicability of these indices was appreciated.

Results. The disease activity by Disease Activity Index for Psoriatic Arthritis (DAPSA) was appreciated as moderate in nearly half of the patients (47.8%), and according to Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) as moderate in 52% of patients. The indices showed the same level of activity in 78% of patients. The indices with the highest correlation were DAPSA vs. BASDAI (r = 0.73), and DAPSA vs. Composite Psoriatic Arthritis Disease Activity Index (CPDAI) (r = 0.70). The applicability of the indices was assessed as moderate to high.

Déclaration d'intérêts. Les auteurs déclarent ne pas avoir de conflits d'intérêts concernant les données publiées dans cet article.

L’article a été soumis en octobre 2020 et accepté en février 2021.

© 2021, the Authors. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Activity Index (BASDAI) moderate disease activity was assessed in 56.5% cases. Minimal disease activity was encountered in only 8.69% of patients. Psoriasis Area and Severity Index (PASI) was estimated as moderate (mean 20.21 points). The data analysis of clinical tools showed that the most affected were pain and general condition, objectified by Visual Analogue Scale (VAS) and Patient Global Assessment (PGA).

**Conclusions.** The DAPSA demonstrated the highest objectiveness and was best able to designate between different levels of disease activity. DAPSA together with Minimal Disease Activity index (MDA), were best related to patient’s quality of life. Therefore, assessing the activity of the disease by MDA and DAPSA can be recommended for use in clinical practice.

**Keywords:** psoriatic arthritis, disease activity measure, quality of life.

**List of abbreviations:**
- PsA – Psoriatic arthritis
- DAPSA – Disease Activity Index for Psoriatic Arthritis
- BASDAI – Bath Ankylosing Spondylitis Disease Activity Index
- PASI – Psoriasis Area and Severity Index
- VAS – Visual Analogue Scale
- PGA – Patient Global Assessment
- MDA – Minimal Disease Activity index
- LDI – Leeds Dactylitis Instrument
- MASES – Maastricht Ankylosing Spondylitis Enthesis Score
- MDGA – Medical Doctor Global Assessment
- TJC – Tender Joint Count
- SJC – Swollen Joint Count
- HAQ – Health Assessment Questionnaire
- ESR – Erythrocyte Sedimentation Rate
- CRP – C-reactive Protein
- HRQoL – Health Related Quality of Life

PsA is a clinically heterogeneous disorder. In addition, the spectrum of the disease features can vary from mild to very severe, representing a challenge for the physician. It is well-known that patients can have any combination of the disease features: peripheral arthritis, enthesitis, dactylitis, spondylitis or sacroiliitis, as well as psoriatic nail disease. Peripheral arthritis is the most common disease manifestation. Another key disease manifestation is enthesitis, defined as inflammation at sites of tendon and ligament attachments. Enthesitis may be asymptomatic or painful and can affect the patient’s function and quality of life, being present in more than half of the patients.

**Résultats.** L’activité de la maladie par DAPSA a été appréciée comme modérée chez 47.8% des patients, selon BASDAI, l’activité modérée de la maladie a été établie dans 56.5% des cas. L’activité minimale de la maladie n’a été rencontrée que chez 8.69% des patients. L’activité cutanée par PASI était modérée (moyenne de 20.21 points). L’analyse des données des outils cliniques a montré que les plus affectés étaient la douleur et l’état général, objectivés par l’échelle visuelle analogue et l’évaluation globale des patients.

**Conclusions.** L’activité de la maladie appréciée par DAPSA a montré une plus grande objectivité, et a prouvé sa supériorité de décision sur les différents niveaux d’activité de la maladie. Le DAPSA associé à l’indice d’activité minimale de la maladie (MDA) étaient mieux corrélés à la qualité de vie des patients. Par conséquence, l’évaluation de l’activité de la maladie à travers MDA et DAPSA peut être recommandée pour l’utilisation dans la pratique clinique.

**Mots-clés:** arthrite psoriasique, mesure de l’activité de la maladie, qualité de la vie.
which tool should be used for remission (<4) and low disease activity (<14)". At the same time, recent research has concentrated on polyarticular patients, in whom the disease activity is proportional to joints counts but may be less illustrative in oligo-arthritis patients in whom despite the high impact of disease, the DAPSA high disease activity cut point is unlikely to ever be reached.

Axial disease in PsA is perhaps the least well-quantified feature of the disease. Significant issues are also being encountered with the outcome measures used in axial PsA. Thus, the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) has been used to measure disease activity in axial PsA and has been shown a good correlation with other disease activity indices. However, it is not able to provide a clear differentiation between axial and peripheral musculoskeletal disease activity with high scores in patients with active peripheral PsA only. Dactylitis, as a component part of the PsA picture, has its impact to the patient’s general condition, by amplifying the disease activity. The only validated tool for assessing dactylitis is the Leeds Dactylitis Instrument (LDI), developed in response to the need for a clinical, objective tool. It measures the ratio of the circumference of the affected digit to the circumference of the digit on the contralateral hand or foot: a minimum difference of 10% is used to define a dactylitic digit. Enthesitis is a unique and important clinical feature of spondyloarthropathy. The Mander Enthesis Index (MEI), the Maastricht Ankylosing Spondylitis Enthesis Score (MASES), the SPondylArthritis Research Consortium of Canada (SPARCC) index, and the Major Enthesitis Index (MEI) were all developed and validated for patients with PsA. Despite on this, the Leeds Enthesitis Index (LEI), which was published in 2008, is the only measure developed specifically for PsA."
both joint and skin disease is a reliable and responsive measure in assessing patient in totality.

The appreciation of the disease activity is the basis in the evaluation of the patient with PsA and is crucial in the election of the treatment strategy, continuous managing the response treatment with the goal of achieving remission or a low/minimal disease activity. This state of the disease signifies that its burden at that time is low and long-term worsening of functioning, quality of life and joint erosion are prevented, and subsequently the prognosis in these conditions is improved. However, for all the presence of the numerous disease activity evaluation tools, the burden of PsA is still high and the reliability of existent tools has to be justified.

THE OBJECTIVE OF THE STUDY was to assess the disease activity level and the evaluation of reliability and applicability of disease activity measures in PsA.

MATERIALS AND METHODS

A descriptive study was conducted between May 2019 and March 2020 in the Rheumatology Department of the Institute of Cardiology, Chisinau, Republic of Moldova. The patients of the study group were selected consecutively and formed a group of 46 subjects with the diagnosis of psoriatic arthritis. The study included patients aged over 18 years old, who signed an informed consent to participate in the study and with the pre-established diagnosis of psoriatic arthritis. The exclusion criteria included rheumatoid arthritis and arthritides of other etiology, as well as patient's refusal. The investigative results were accumulated according to our approved research questionnaire, which contains information on clinical and demographic data: sex, place of residence, marital status, age at onset and duration of disease, patient’s profession and education, as well as characteristics of the disease evaluated by specific clinical tools.

According to the aim of the study, the level of the PsA disease activity was quantified by DAPSA, considered gold standard for this disease, and BASDAI which is largely used for reactive arthritis. Regarding to a specifically appreciation of a Minimal Disease Activity (MDA), we aimed to determine the rate of remissions and low disease activity in our patients. To calculate disease activity indices, there where appreciated the following components: a full traditional 66/68 evaluation of TJC/SJC, as well as joint pain appreciated by visual analogue scale (VAS), the global assessment of the patient’s condition by estimating PGA (Patient Global Assessment) and MDGA (Medical Doctor Global Assessment), appreciated by 100 mm scale. Simultaneously, to provide a quantitative assessment of psoriasis lesion burden based on the amount of BSA involved and degree of severity of erythema, induration, and scale, weighted by body part, PASI was evaluated. Furthermore, MASES, recommended by the Spondylarthritis International Society for use in randomized controlled trials of axial spondylitis and spondylarthritides, was used to assess enthesis in our study patients. Physical function was reliably assessed in our patients by using Health Assessment Questionnaire (HAQ), which is a component of MDA index.

The study was conducted in accordance with the Helsinki Declaration on Human Rights, as well as the national law. The study design was approved by the Ethics Committee of the Institute of Cardiology, Chisinau (24 December 2012). Written informed consent was obtained from all participants, according to the Declaration of Helsinki.

The statistical processing of the research data was carried out with the help of Microsoft Excel and MedCalc v.1.2 programs. The mean values (M), the arithmetic mean (t), and the validity of the differences p according to Student’s t-distribution were evaluated and displayed in boxplot. The difference in indices was considered probable at p<0.05 according to Student’s t-test distribution. The degree of correlation was calculated by the Pearson test, where absolute value of r and strength of r was considered: r < 0.3 none or very weak, 0.3 < r <0.5 weak, 0.5 < r < 0.7 moderate and r > 0.7 strong.

RESULTS

In accordance with the established tasks, the study group included 46 patients with PsA who met the pre-established inclusion criteria. We analyzed the demographic parameters in the examined patients; the obtained results were shown in Table 1. The data reveal the predominance of men (54.35%) in the study group, with a female to male ratio of 1.19: 1. After the segregation of the subjects from the study group according to the place of residence, we highlighted their preponderance in the urban space. Next, we analyzed the marital status of patients and found that 80.43% of patients lived with families, being married, 8.04% were divorced and 4.35% single at the time of research. 6.52% of the subjects included in the study were widows(ers). We took into account the persons living with the study patients at the moment of the examination and found that 41.3% and 47.83% of patients lived with their spouse, partner or children, when every tenth person lived alone. Afterward, we were interested in assessing the disease risk factors, finding that 56.52% of cases did
not notice the causes that could trigger the disease, thereby 15% of women reported wearing heels, and 13.04% were at menopause; likewise, physical activity and sports or trauma were detected in 4.35% and 10.87% of cases, respectively.

We continued the research by estimating the patient’s age and the disease duration (Table 2). We concluded that patients with PsA had a mean age of 48 years (aged between 19 and 70 years). Regarding the duration of the disease, it varied widely (15 – 502 months), with a mean of 164 months, which is about 14 years.

According to the objectives, we used international indices to assess the activity of the disease: DAPSA, which is the gold standard, and BASDAI, used in patients with axial impairment. The results of the disease activity assessment by DAPSA index are presented in Figure 1.

The analysis of the data presented in Figure 1 demonstrates that the mean ± SD disease activity according to the DAPSA index was 27.33±15.76 points, with wide variational interval, from 9.2 to 74.6 points. About 2/3 of the index level was within the limits of 15-30 points. Subsequently, we segregated the activity of the disease according to the status of the DAPSA index in remission, low, moderate and high activity (Figure 2). The data reflect that at the time of inclusion in the study, no remission was found in the subjects, at the same time low activity was detected in

---

**Table 1.** Demographic data of patients in the study group

| Variable                | Patients, No | (%)  |
|-------------------------|--------------|------|
| Gender:                 |              |      |
| Women                   | 21           | 45.65|
| Men                     | 25           | 54.35|
| Place of residence:     |              |      |
| Rural                   | 22           | 47.83|
| Urban                   | 24           | 52.17|
| Marital status:         |              |      |
| Married                 | 37           | 80.43|
| Divorced                | 4            | 8.70 |
| Bachelor                | 3            | 4.35 |
| Widower                 | 2            | 6.52 |
| Living with:            |              |      |
| Spouse / Partner        | 19           | 41.30|
| children                | 22           | 47.83|
| Single                  | 5            | 10.70|
| Risk factors:           |              |      |
| Intense physical activity/ sports | 2 | 4.35 |
| Knee injuries           | 5            | 10.87|
| Menopause               | 6            | 13.04|
| Wearing high-heeled shoes | 7       | 15.22|
| Absence of risk factors | 26           | 56.52|

---

**Table 2.** Clinical-demographic parameters of the study group

| Parameters                        | Duration | Variation interval |
|-----------------------------------|----------|--------------------|
| Mean age at the time of the research, years | 47.23±9.2 | 19-70              |
| Mean duration of the disease, months      | 164.78±92.81 | 15-502             |
| Time from the onset of arthritis, months | 28.22±38.51 | 13-104             |

---

**Figure 1.** The activity of PsA according to the DAPSA index in the study group.
13.04%, moderate in 47.83% and high disease activity was detected in 39.13% of cases.

We determined the activity through another important index used in rheumatology, BASDAI (Figure 3). The examination of the BASDAI activity results related a mean ± SD of 5.27±1.84 (between 2.4-9.6 p), considered high in 24 (26.09%) patients, which represent similar data with Cerlat et al (2011)\(^\text{10}\) and differ from the data of Wong et al (2012)\(^\text{7}\). Regarding the score with moderate values, there were 52 (56.52%) subjects in our study. At the same time, the score with low values was found in 17.39% of patients\(^\text{11}\).

Consequently, we were interested in researching the group of patients through the Minimal Disease Activity Index, revised in 2019 by Coates\(^\text{12}\), to determine the number of patients with disease minimal activity or remission and their proportion in the research group (Table 3). The data show that only 4 patients (8.69%) did not present symptoms like joint pain, while the absence of the swollen joints was more frequent, in 39.13% of cases, which means that the pain predominated. The pain assessed by VAS coincided with the painful joints – TJA. An index taken into account was the overall self-assessment (PGA), which showed that only 6 (13.04%) patients out of the 46 examined rated their condition as good (less than 20 mm), the enthesitis score in one third of the examined subjects was less than one, considered low. The PhGA included in HAQ was detected in a low level (below 0.5 points) in 26 (56.52%) subjects. Thus, analyzing the data presented in Table 3, we highlighted that only four (8.69%) patients had minimal disease activity.

We intended to evaluate the groups according to the main indices used in PsA (Table 4). The analysis of the parameters, according to the clinical instruments, from the patient’s research file is presented, respectively eight parameters. One of the parameters evaluated was the TJC and we noted the predominance of the moderate value (39.14%), while the severe and low values were also frequent (26.08%). The evaluation of the swollen joints showed the absence of swelling in 17.39% of cases, the predominant number reflected in the low value score group, observed in 47.83% patients. At the same time, we estimated the skin involvement in patients from the study group, highlighting the score with moderate values in 65.22% of subjects as the most frequent.

We were interested in assessing pain and general

| Parameters | Patient's number | %   | n-i   |
|------------|------------------|-----|-------|
| TJC        | 4                | 8.69| 0-1.0 |
| SJC        | 18               | 39.13| 0-1.0 |
| PASI       | 2                | 4.34| 0-1.0 |
| VAS        | 4                | 8.69| 0-15.0|
| PGA        | 6                | 13.04| 0-20.0|
| HAQ        | 26               | 56.52| 0-0.5 |
| MASES      | 14               | 30.43| 0-1.0 |
condition through self-administered VAS and PGA instruments. In fact, we obtained a small discrepancy between the general condition and the pain, PGA appreciated more severe. Of particular interest was the enthesial score, MASES, which objectifies enthesopathies by assessing the presence or absence of tenderness in the 13 enthesial sites and is considered an important tool in the evaluation of psoriatic arthritis. The results of the enthesopathies evaluation showed low values in most of the patients, 73.91% cases. In conclusion, based on the obtained results, the most affected areas were pain and general condition, objectified by PGA.

The data from the Table 5 show that patients had pain varied from 19 to 81 mm, with the mean value of 55.13 – moderate pain. Regarding to patient

| Indices | Value 0- remission | Low value score | Moderate value score | High value score |
|---------|-------------------|-----------------|----------------------|-----------------|
| TJC (No) | 4 (8.70) | 0 | 12 (26.08) | 1-4 | 18 (39.14) | 5-10 | 12 (26.08) | >10 |
| SJC (No) | 8 (17.39) | 0 | 22 (47.83) | 1-3 | 2 (4.35) | 4-5 | 14 (30.43) | >5 |
| PASI (p) | 2 (4.35) | 0-1 | 12 (26.08) | 2-10 | 30 (65.22) | 11-40 | 2 (4.35) | >40 |
| PGA (mm) | 0 (0) | 0-10 | 8 (17.39) | 10-30 | 22 (47.83) | 40-70 | 16 (34.78) | >70 |
| VAS (mm) | 2 (4.35) | 0-10 | 4 (8.70) | 10-30 | 26 (56.52) | 40-70 | 14 (30.43) | >70 |
| DAPSA (p) | 0 (0) | 0-4 | 6 (13.04) | 5-14 | 22 (47.83) | 15-28 | 18 (39.13) | >28 |
| BASDAI (points) | 11 (23.91) | 0-10 | 26 (56.52) | 4-6 | 9 (19.57) | >6 |
| MASES (points) | 2 (4.35) | 0 | 32 (69.57) | 1-4 | 10 (21.73) | 5-10 | 2 (4.35) | >10 |

| Parameter | Mean value ± SD | Variational interval |
|-----------|-----------------|----------------------|
| VAS (mm) | 55.13 ± 18.81 | 19-81 |
| PGA (mm) | 60.17 ± 16.85 | 25-84 |
| MDGA (mm) | 58.09 ±16.88 | 22-85 |
| PASI (points) | 20.21 ±9.69 | 0.6-46.8 |
| DAPSA (points) | 27.33 ±15.76 | 9.2-74.6 |
| BASDAI (points) | 5.27 ±1.84 | 2.4-9.6 |
| MASES (points) | 3.09 ±2.20 | 0-8 |

| Parameters | DAPSA | BASDAI | MDGA | PGA | VAS | MASES | TJC | SJC |
|------------|-------|--------|------|-----|-----|-------|-----|-----|
| DAPSA | r=0.48 | r=0.53 | r=0.55 | r=0.45 | r=0.27 | r=0.02 | r=0.82 | r=0.007 | r=0.0002 | r=0.0001 | r=0.0001 | r=0.0001 |
| BASDAI | r=0.53 | r=0.53 | r=0.55 | r=0.45 | r=0.27 | r=0.02 | r=0.82 | r=0.007 | r=0.0002 | r=0.0001 | r=0.0001 | r=0.0001 |
| MDGA | r=0.55 | r=0.55 | r=0.55 | r=0.54 | r=0.47 | r=0.28 | r=0.12 | r=0.001 | r=0.0002 | r=0.0001 | r=0.0001 | r=0.0001 |
| PGA | r=0.45 | r=0.45 | r=0.45 | r=0.54 | r=0.47 | r=0.28 | r=0.12 | r=0.001 | r=0.0002 | r=0.0001 | r=0.0001 | r=0.0001 |
| VAS | r=0.27 | r=0.27 | r=0.27 | r=0.21 | r=0.47 | r=0.18 | r=0.11 | r=0.001 | r=0.0002 | r=0.0001 | r=0.0001 | r=0.0001 |
| MASES | r=0.92 | r=0.92 | r=0.92 | r=0.37 | r=0.28 | r=0.18 | r=0.74 | r=0.001 | r=0.0002 | r=0.0001 | r=0.0001 | r=0.0001 |
| TJC | r=0.33 | r=0.33 | r=0.33 | r=0.33 | r=0.33 | r=0.33 | r=0.33 | r=0.001 | r=0.0002 | r=0.0001 | r=0.0001 | r=0.0001 |
| SJC | r=0.24 | r=0.24 | r=0.24 | r=0.24 | r=0.24 | r=0.24 | r=0.24 | r=0.001 | r=0.0002 | r=0.0001 | r=0.0001 | r=0.0001 |
and physician global assessments we note the similar values, however patient’s appreciation was higher than the doctor’s within 2 mm in average. The disease activity assessment by DAPSA and BASDAI obtained the moderate disease activity with the tendency to high activity appreciated by DAPSA. The enthesial score appreciated in patients from the study group showed to be low, 3.09 points in average. More than 60% of patients with PsA had cutaneous manifestations on the moment of the visit, thus the psoriatic disease activity was appreciated as moderate (mean PASI value 20.21 points).

We were interested in performing a correlative analysis of present activity disease indices. First, we analyzed the total DAPSA and BASDAI indices correlation and determined a moderate clinic significant correlation ($r=0.488$, $p=0.007$) reflected in Figure 3. These data show that both indices are effective in appreciation of disease activity in patients with PsA, in general; besides, we detected a link in these two

Figure 3. PsA activity according to the BASDAI index in the study group.

Figure 4. The correlation of DAPSA and BASDAI activity indices in the study group.
indices, which means that the reliability of disease activity appreciation in our patients was high.

The correlative analysis of the indices we used for the appreciation of patient’s general condition by himself or by the physician and the pain evaluation was correlated with all the indices, which influences the patient’s general wellbeing.

In the context of interrelation of global assessment, we were interested to correlate the patient’s and physician’s global assessment, and attained a strong statistically significant correlation, \( r=0.958 \), \( p<0.001 \) (Figure 4). The further correlations of activity indices are presented in Table 6.

As presented in Table 6, the important correlations were found in DAPSA with all activity measures, excluding enthesis score. Concerning the BASDAI, we detected the relations with pain and enthesis score as well as joint counts, in addition to DAPSA. Considering the VAS, it correlates with all indices, with exception of SJC. Distinguishing the enthesis score, the correlation was noted only with BASDAI and VAS, which is influenced by the presence of non-articular pain and discomfort, and the subjectiveness of Bath score. The interdependence of joint counts and their influence on the most indices of disease activity is evident. The interrelation of activity indices and PASI score was not found, with the exception of patient’s global assessment (\( r=0.283 \), \( p<0.008 \)), which is evident, that psoriatic eruptions are causing a discomfort for patient, related with the patient’s global score. An important issue in patient’s appreciation was the assessment of disability or impact of the disease on his everyday life, which was appreciated by HAQ, and this index correlated (\( r=0.24 \), \( p<0.05 \)) only with DAPSA, thus being more representative by this activity index.

The correlative analysis of inflammatory markers revealed that the most sensible in our study was erythrocyte sedimentation rate (ESR), which correlated with all clinical tools, except for MASES, while the C-reactive protein (CRP) correlates with DAPSA, BASDAI and MASES scores.

**Discussion**

Psoriasis and PsA is included in the World Health Organization (WHO) and Global Burden of Disease (GBD) work. The goal of the activity measure tools in PsA is to assess and monitor the disease activity from the onset and its evolution, the applicability of basic treatment of PsA for optimizing the functionality and health-related quality of life (HRQOL), and to prevent structural damage. This can be done by aiming at remission or, if this cannot be achieved, low or minimal disease activity\(^{11,13}\).

Disease activity is determined using composite measures, in which multiple aspects of the disease are bent together in a total score of disease activity level. Thus, multiple disease activity measures are available and used in PsA. As a more PsA-specific measure, DAPSA was developed using the 66/68 joint count. For clinical practice, use of either DAPSA, BASDAI or MDA is helpful\(^6\). Although all measures are able to distinguish different levels of disease activity, studies have shown that disease activity level is often moderate. Disease activity in patients from this study was predominantly moderate to severe, in 2/3 of subjects.

This study assessed the responsiveness of some composite measures in the usual care of PsA, including BASAI and DAPSA, which showed high objectivity. Regarding the relation of a disease activity measure and HRQOL, patients in MDA report better HRQOL than patients not in MDA\(^4\). The superiority of DAPSA and MDA in transversal study could be attributed to their multidimensionality, but also to the use of more extensive questionnaires than for VAS scores alone. The main indices are influenced by other factors than active disease: an increase in acute phase reactants—considered an objective measure of disease activity—can have other causes than an increase in PsA activity; in our study, the inflammatory markers correlated with both DAPSA and BASDAI. A composite measure needs the interpretation of a physician, who can choose a treatment strategy if a higher disease activity score has other causes than PsA activity, that is why the tools of the disease activity assessment must be complex, as against to PGA, VAS or MDGA, which also can be influenced by subjective factors. The global assessment of patients with PsA demonstrated levels higher than moderate, with the overestimation of the disease by patients in comparison with their doctors.

The important sign of the disease, which decreases the quality of life, is pain, which was moderate to high in our patients and interdependent with all the indices used by us. The close correlation of VAS was found with global assessments, DAPSA, BASDAI, MASES and TJC, only the number of swollen joints did not influence the patient’s pain level. The correlative analysis of the activity assessment tools highlighted that DAPSA takes into consideration the most important measures for the activity appreciation; moreover, the sensibility of this index is confirmed by more objective MDGA correlation and inflammatory response. Obviously, the CRP, which is included in this index, likewise the ESR, not included, are related to DAPSA. The less important correlation of BASDAI with activity indices, including MDGA and SJC, can be explained by the specific
questions in this questionnaire, which refers to axial spondyloarthritis, while patients with PsA do not always have these symptoms. The other cause, which can also be referred to the absence of correlation with the MDGA, could be the subjectiveness of the given questions in BASDAI index. As against to the DAPSA index, which consists of PGA and VAS evaluation and correlates significantly with the strong relation between these measures, BASDAI is less sensible in this appreciation. Besides, the DAPSA has a strong clinically significant correlation with the MDGA. In clinical practice, the assessment of the musculoskeletal disease activity should include all joints, presence of enthesitis and dactylitis; however, in our study the enthesial score did not show an important relation to other clinical tools, excepting BASDAI and VAS, but it is also important to evaluate these symptoms to create the full picture of the disease.

The assessment of every system implicated in the variety of the PsA clinical picture is important for the management of the disease. The time needed to perform all these clinical tools is important and the insufficient doctor’s time guides the necessity of a one complex clinical tool for PsA disease activity appreciation.

CONCLUSIONS

Given the complexity of PsA, the estimation of disease activity needs to consider the important domains to assess their impact on the patient and the response to treatment. The disease activity measure DAPSA demonstrated the highest objectiveness and was more able to designate between different levels of disease activity. DAPSA together with MDA were best related to patient’s quality of life. Therefore, assessing the activity of the disease by MDA and DAPSA can be recommended for use in the clinical practice.

Authors’ contribution

T.R. and M.G. drafted the first manuscript, N.L.O. and M.G. acquired and interpreted the data, T.R., L.M.N. and M.M. designed the trial, M.M. and V.S., V.S.B. revised the manuscript critically. All the authors revised and approved the final version of the manuscript.

Compliance with Ethics Requirements:

“The authors declare no conflict of interest regarding this article”

“The authors declare that all the procedures and experiments of this study respect the ethical standards in the Helsinki Declaration of 1975, as revised in 2008(5), as well as the national law. Informed consent was obtained from all the patients included in the study”

“No funding for this study”

Acknowledgments: none

REFERENCES

1. Kerschbaumer A, Fendl KH, Erlacher L, Aletaha D. An overview of psoriatic arthritis – epidemiology, clinical features, pathophysiology and novel treatment targets. Andreas, Wien Klin Wochenschr. 2016:128(21): 791–795.
2. Ogdie A, Wiess P. The epidemiology of psoriatic arthritis. Rheum Dis Clin North Am. 2015; 41(4): 545–568.
3. Chandran V, Maharaj AB. Assessing disease activity in psoriatic and psoriatic arthritis: impact on management and therapy. Expert Rev Clin Immunol. 2016:12(5):573-82.
4. Kahyoncu U, Ogdie A, Campbell W, et al. Systematic literature review of domains assessed in psoriatic arthritis to inform the update of the psoriatic arthritis core domain set. RMD Open. 2016:2(1):e000217.
5. Smolen JS, Schols M, Braun J, et al. Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force. Ann Rheum Dis. 2018;77(1): 3–17.
6. Schoels M, Aletaha D, Alasti F, et al. Disease activity in psoriatic arthritis (PsA): defining remission and treatment success using the DAPSA score. Ann Rheum Dis. 2016:75(5):811-8.
7. Wong PC, Leung YY, Li EK, Tam LS. Measuring disease activity in psoriatic arthritis. Int J Rheumatol. 2012;89425.
8. Gottlieb A, Merola JF. Psoriatic arthritis for dermatologists. Journal of Dermatological Treatment. 2019:31(1):662-679.
9. Caucci A, Gladman DD, Mathieu A, et al. Patient global assessment in psoriatic arthritis: a multicentre GRAPPA and OMERACT study. J Rheumatol. 2011;38(5):898-903.
10. Cerlat E, Gorea O, Mazur-Nicorici L, et al. Rolul instrumentelor clinice și radioimagistice în diagnosticul afectării axiale în artrita psoriatică. Analele Stiintifice ale USMF “Nicolea Testemitanu.” 2011:12(3):114-119.
11. Gossec L, Smolen JS, Ramiro S, et al. European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update. Ann Rheum Dis. 2016:75:499-510.
12. Coates LC, Strand V, Wilson H, et al. Measurement properties of the minimal disease activity criteria for psoriatic arthritis. RMD Open. 2019:5(2):e001002.
13. Coates LC, Kavanaugh A, Mease PJ, et al. Group for Research and Assessment of Psoriasis and Psoriatic Arthritis 2015 treatment recommendations for psoriatic arthritis. Arthritis Rheumatol. 2016:68:1060–71.
14. Gratacos J, Daudén E, Gómez-Reino J, et al. Health-related quality of life in psoriatic arthritis patients in Spain. Reumatología Clínica (English Edition). 2014:10(1):25–31.
15. Cseppento C, Cevei M, Cioclar F, Bungau S. Psychological and functional impact of HIP arthritis and coxitis of rheumatoid arthritis and ankylosing spondylitis. Osteoparos Int. 2011;22 (Suppl. 1):387-388.
16. Chadha S, Behl T, Kumar A, et al. Mechanistic insights into the role of pyroptosis in rheumatoid arthritis. Curr Res Translat Med. 2020; 68(4):151-158.